On Thursday 25 May, AdAlta’s CEO and Managing Director, Dr Tim Oldham presented at an in-person Twilight Investor briefing in Melbourne along with our collaboration partner, Carina Biotech’s CEO, Dr Deborah Rathjen.
Dr Oldham explained AdAlta’s current areas of strategic focus, including lead program AD-214, our CAR-T cell therapy program and progress on partnering opportunities.
The event was hosted by Peak Asset Management, the corporate advisor for AdAlta’s recent Rights Offer.
To watch a recording of the event (presentation slides and audio), click below.
The presentation slides can also be viewed by CLICKING HERE